All the hullabaloo over pharma's drug-pricing practices has taken its toll on several of the industry's stocks. But not Gilead Sciences ($GILD) and Regeneron ($REGN): While both sank in September on Hillary Clinton's announcement that she'd be cracking down on "price-gouging," they've climbed their way back up. Harder-hit companies like Valeant ($VRX) and Mallinckrodt ($MNK), however, haven't been able to pull that off. More